Misako Nagasaka, ELCC 2022: Results of the TRUST-II Study
touchONCOLOGY spoke to Prof Misako Nagasaka (University of California Irvine, Detroit, MI, USA) to discuss her presentation at the European Lung Cancer Congress 2022, providing the results of the TRUST-II study, a global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumours.
Questions
- Â Â Â What is taletrectinib and in what tumours is it indicated? 00:16-01:12
- Â Â Â What were the aims and design of the TRUST-II study? 01:12-02:37
- Â Â Â What were the findings in terms of overall response rate and disease control rate? 02:37-04:03
- Â Â Â Â What is the safety profile of taletrectinib? 04:03-04:55
- Â Â Â What will be the next steps in the clinical development of taletrectinib? 04:55-05:35
Speaker Disclosure: Misako Nagasaka is a consultant for: AnHeart, Caris Life Sciences and Lilly. She is part of the Advisory Board for: AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Janssen, Mirati, Novartis, Pfizer, Regeneron and Silverback. She is a Speaker’s Bureau participant with: Takeda and Blue Print Medicines.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Congress 2022